Evidence map›Paper›PMID 38617226›Full record

ArticlebioRxiv : the preprint server for biology2024

Structural Models for a Series of Allosteric Inhibitors of IGF1R Kinase.

Jyoti Verma, Harish Vashisth

Open access · greenAbstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Jyoti VermaDepartment of Chemical Engineering and Bioengineering, University of New Hampshire, Durham, NH 03824, USA.
Harish VashisthDepartment of Chemical Engineering and Bioengineering, University of New Hampshire, Durham, NH 03824, USA.ORCID 0000-0002-2087-2880
University of New Hampshire · US

Funding

TLR-TRIF mediated induction of GLI3 modulates innate inflammatory responsesP20GM113131 · NIGMS · UNIVERSITY OF NEW HAMPSHIRE · PI W Kelley THOMAS · 2017 to 2026
$22.8M
Peptides and Small-molecules Targeting Signaling Proteins and Protein-Protein InterfacesR35GM138217 · NIGMS · UNIVERSITY OF NEW HAMPSHIRE · PI Harish Vashisth · 2020 to 2026
$2.9M
NIGMS NIH HHS P20 GM113131NIGMS NIH HHS R35 GM138217
6 · The paper itself

Abstract

The allosteric inhibition of Insulin-like Growth Factor Receptor 1 Kinase (IGF1RK) is a potential strategy to overcome selectivity barriers in targeting receptor tyrosine kinases. We constructed structural models of a series of 12 indole-butyl-amine derivatives which have been reported as allosteric inhibitors of IGF1RK. We further studied dynamics and interactions of each inhibitor in the allosteric pocket via all-atom explicit-solvent molecular dynamics (MD) simulations. We discovered that a bulky carbonyl substitution at the R1 indole ring is structurally unfavorable for inhibitor binding in the IGF1RK allosteric pocket. Moreover, we found that the most potent derivative (termed C11) acquires a distinct conformation, forming an allosteric pocket channel with better shape complementarity and interactions with the receptor. In addition to a hydrogen bonding interaction with V1063, the cyano derivative C11 forms a stable hydrogen bond with M1156, which is responsible for its unique binding conformation in the allosteric pocket. Our findings show that the position of chemical substituents at the R1 indole ring with different pharmacophore features influences molecular interactions and binding conformations of the indole-butyl-amine derivatives, hence dramatically affecting their potencies. Our results provide a structural framework for the design of allosteric inhibitors with improved affinities and specificities against IGF1RK.

Indexed as

allosteric inhibitorsinsulin-like growth factor receptor 1 kinasemolecular dockingmolecular dynamicspharmacophore modeling

Identifiers

PMID38617226
PMCPMC11014618
OpenAlexW4394063372

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.